MELBOURNE, Australia, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing new treatments for patients suffering from recurrent and metastatic cancer, today announced a strategic initiative to pursue the acquisition of Digital Asset Treasury (DAT) companies that are currently trading below their Market Cap to Net Asset Value (MNAV). The Company’s management believes that acquiring undervalued DAT entities presents a com ...